Exact Mass: 427.2045
Exact Mass Matches: 427.2045
Found 500 metabolites which its exact mass value is equals to given mass value 427.2045
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Moricizine
Moricizine is only found in individuals that have used or taken this drug. It is an antiarrhythmia agent used primarily for ventricular rhythm disturbances. [PubChem]Moricizine works by inhibiting the rapid inward sodium current across myocardial cell membranes. D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Ranolazine
Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia. C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Dihydroxyacidissiminol
Dihydroxyacidissiminol is found in beverages. Dihydroxyacidissiminol is an alkaloid from fruits of Limonia acidissima (wood apple). Alkaloid from fruits of Limonia acidissima (wood apple). Dihydroxyacidissiminol is found in beverages and fruits.
6-Hydroxyfluvastatin
6-Hydroxyfluvastatin is only found in individuals that have used or taken Fluvastatin. 6-Hydroxyfluvastatin is a metabolite of Fluvastatin. 6-hydroxyfluvastatin belongs to the family of Indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene to form 2,3-benzopyrrole.
5-Hydroxyfluvastatin
5-Hydroxyfluvastatin is only found in individuals that have used or taken Fluvastatin. 5-Hydroxyfluvastatin is a metabolite of Fluvastatin. 5-hydroxyfluvastatin belongs to the family of Indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene to form 2,3-benzopyrrole.
(1-(2-(Methylsulfonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-2-methoxy-1H-indole-3-carboxylate
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
Dixyrazine
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D005765 - Gastrointestinal Agents > D000932 - Antiemetics
Mozavaptan
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
Tropantiol
(2R,3R,4S,5S,6R)-2-(3-(4-Cyclopropylbenzyl)-4-fluoro-1H-indol-1-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
Valyl-prolyl-glycyl-valyl-glycine
Dixyrazine
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D005765 - Gastrointestinal Agents > D000932 - Antiemetics CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu); Flow Injection CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu); CONFIDENCE Reference Standard (Level 1)
(1aS,2aS,5S,5aS,6S,6aR)-5-benzylhexahydro-2a-hydroxy-2-[(1E,4S,6S)-6-hydroxy-4-methyl-5-oxohept-1-enyl]-6,6a-dimethyl-3H-oxireno[f]isoindol-3-one|cytochalasin Z20
(7R)-8t-acetoxy-6,7-dimethoxy-2-methyl-6,8,3,4-tetrahydro-2H-(7rN)-spiro[indeno[4,5-d][1,3]dioxole-7,1-isoquinolin]-6t-ol|Raddeanidin|Raddeanidine
2-[[2-[(2-amino-3-phenyl-propanoyl)amino]-3-methyl-butanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
Lasiocarpine N-oxide
Lasiocarpine N-oxide is a natural product found in Heliotropium hirsutissimum and Heliotropium ellipticum with data available.
8-benzyl-9,10-dimethoxy-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline
relative retention time with respect to 9-anthracene Carboxylic Acid is 0.995
RANOLAZINE
C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
(2R,2R,4aS,6R,8aS)-4-hydroxy-2,5,5,8a-tetramethyl-6-oxo-3,3,4,4a,5,6,6,7,7,8,8,8a-dodecahydro-2H-spiro[furo[2,3-e]isoindole-2,1-naphthalen]-6-yl acetate
Ala His Asn Ser
Ala His Ser Asn
Ala Ile Pro Gln
Ala Ile Gln Pro
Ala Leu Pro Gln
Ala Leu Gln Pro
Ala Asn His Ser
Ala Asn Ser His
Ala Pro Ile Gln
Ala Pro Leu Gln
Ala Pro Gln Ile
Ala Pro Gln Leu
Ala Gln Ile Pro
Ala Gln Leu Pro
Ala Gln Pro Ile
Ala Gln Pro Leu
Ala Ser His Asn
Ala Ser Asn His
Gly His Lys Ser
Gly His Asn Thr
Gly His Gln Ser
Gly His Ser Lys
Gly His Ser Gln
Gly His Thr Asn
Gly Lys His Ser
Gly Lys Ser His
Gly Asn His Thr
Gly Asn Thr His
Gly Pro Arg Val
Gly Pro Val Arg
Gly Gln His Ser
Gly Gln Ser His
Gly Arg Pro Val
Gly Arg Val Pro
Gly Ser His Lys
Gly Ser His Gln
Gly Ser Lys His
Gly Ser Gln His
Gly Thr His Asn
Gly Thr Asn His
Gly Val Pro Arg
Gly Val Arg Pro
His Ala Asn Ser
His Ala Ser Asn
His Gly Lys Ser
His Gly Asn Thr
His Gly Gln Ser
His Gly Ser Lys
His Gly Ser Gln
His Gly Thr Asn
His Lys Gly Ser
His Lys Ser Gly
His Asn Ala Ser
His Asn Gly Thr
His Asn Ser Ala
His Asn Thr Gly
His Gln Gly Ser
His Gln Ser Gly
His Ser Ala Asn
His Ser Gly Lys
His Ser Gly Gln
His Ser Lys Gly
His Ser Asn Ala
His Ser Gln Gly
His Thr Gly Asn
His Thr Asn Gly
Ile Ala Pro Gln
Ile Ala Gln Pro
Ile Pro Ala Gln
Ile Pro Gln Ala
Ile Gln Ala Pro
Ile Gln Pro Ala
Lys Gly His Ser
Lys Gly Ser His
Lys His Gly Ser
Lys His Ser Gly
Lys Pro Pro Ser
Lys Pro Ser Pro
Lys Ser Gly His
Lys Ser His Gly
Lys Ser Pro Pro
Leu Ala Pro Gln
Leu Ala Gln Pro
Leu Pro Ala Gln
Leu Pro Gln Ala
Leu Gln Ala Pro
Leu Gln Pro Ala
Asn Ala His Ser
Asn Ala Ser His
Asn Gly His Thr
Asn Gly Thr His
Asn His Ala Ser
Asn His Gly Thr
Asn His Ser Ala
Asn His Thr Gly
Asn Pro Pro Thr
Asn Pro Thr Pro
Asn Pro Val Val
Asn Ser Ala His
Asn Ser His Ala
Asn Thr Gly His
Asn Thr His Gly
Asn Thr Pro Pro
Asn Val Pro Val
Asn Val Val Pro
Pro Ala Ile Gln
Pro Ala Leu Gln
Pro Ala Gln Ile
Pro Ala Gln Leu
Pro Gly Arg Val
Pro Gly Val Arg
Pro Ile Ala Gln
Pro Ile Gln Ala
Pro Lys Pro Ser
Pro Lys Ser Pro
Pro Leu Ala Gln
Pro Leu Gln Ala
Pro Asn Pro Thr
Pro Asn Thr Pro
Pro Asn Val Val
Pro Pro Lys Ser
Pro Pro Asn Thr
Pro Pro Gln Ser
Pro Pro Ser Lys
Pro Pro Ser Gln
Pro Pro Thr Asn
Pro Gln Ala Ile
Pro Gln Ala Leu
Pro Gln Ile Ala
Pro Gln Leu Ala
Pro Gln Pro Ser
Pro Gln Ser Pro
Pro Arg Gly Val
Pro Arg Val Gly
Pro Ser Lys Pro
Pro Ser Pro Lys
Pro Ser Pro Gln
Pro Ser Gln Pro
Pro Thr Asn Pro
Pro Thr Pro Asn
Pro Val Gly Arg
Pro Val Asn Val
Pro Val Arg Gly
Pro Val Val Asn
Gln Ala Ile Pro
Gln Ala Leu Pro
Gln Ala Pro Ile
Gln Ala Pro Leu
Gln Gly His Ser
Gln Gly Ser His
Gln His Gly Ser
Gln His Ser Gly
Gln Ile Ala Pro
Gln Ile Pro Ala
Gln Leu Ala Pro
Gln Leu Pro Ala
Gln Pro Ala Ile
Gln Pro Ala Leu
Gln Pro Ile Ala
Gln Pro Leu Ala
Gln Pro Pro Ser
Gln Pro Ser Pro
Gln Ser Gly His
Gln Ser His Gly
Gln Ser Pro Pro
Arg Gly Pro Val
Ser Ala His Asn
Ser Ala Asn His
Ser Gly His Lys
Ser Gly His Gln
Ser Gly Lys His
Ser Gly Gln His
Ser His Ala Asn
Ser His Gly Lys
Ser His Gly Gln
Ser His Lys Gly
Ser His Asn Ala
Ser His Gln Gly
Ser Lys Gly His
Ser Lys His Gly
Ser Lys Pro Pro
Ser Asn Ala His
Ser Asn His Ala
Ser Pro Lys Pro
Ser Pro Pro Lys
Ser Pro Pro Gln
Ser Pro Gln Pro
Ser Gln Gly His
Ser Gln His Gly
Ser Gln Pro Pro
Thr Gly His Asn
Thr Gly Asn His
Thr His Gly Asn
Thr His Asn Gly
Thr Asn Gly His
Thr Asn His Gly
Thr Asn Pro Pro
Thr Pro Asn Pro
Thr Pro Pro Asn
Val Asn Pro Val
Val Asn Val Pro
Val Pro Asn Val
Val Pro Val Asn
Val Val Asn Pro
Val Val Pro Asn
20-hydroxy N-Arachidonoyl Taurine
Dihydroxyacidissiminol
7-(2,2-Diphenylethenyl)-1,2,3,3A,4,8B-hexahydro-4-(4-methylphenyl)cyclopent[B]indole
Pentaerythritol tris-[3-(1-aziridinyl)-propionate]
2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate
21-Amino-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione hydrochloride
Flavoxate hydrochloride
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D000089162 - Genitourinary Agents > D064804 - Urological Agents Flavoxate hydrochloride is a potent and competitive phosphodiesterase (PDE) inhibitor. Flavoxate hydrochloride is an antispasmodic agent and muscarinic mAChR antagonist. Flavoxate hydrochloride shows moderate calcium antagonistic activity and local anesthetic effect. Flavoxate hydrochloride can be used for the research of overactive bladder (OAB) and lower urinary tract infections[1].
bis[tris(dimethylamino)-λ5-phosphanylidene]azanium,tetrafluoroborate
(S,E)-3-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)AMINO)-6-PHENYLHEX-5-ENOIC ACID
4-(2-HYDROXYETHYL)-3-METHYL-5-OXO-2,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXIMIDAMIDE
3-[3-tert-butyl-5-(5-chlorobenzotriazol-2-yl)-4-hydroxyphenyl]propyl 2-methylprop-2-enoate
2-[2-[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-4-yl]methyl-(2-sulfanylethyl)amino]ethylamino]ethanethiol
Trospium Chloride
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D000089162 - Genitourinary Agents > D064804 - Urological Agents Trospium chloride is an orally active, specific and competitive antagonist of muscarinic cholinergic receptors (mAChRs), with antimuscarinic activity. Trospium chloride binds to muscarinic receptors M1, M2 and M3 with high affinity, but not nicotinic, cholinergic receptors[1][2].
Panomifene
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist
Oxyphenonium bromide
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D009184 - Mydriatics C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent Oxyphenonium bromide is an antiacetylcholine compound. Oxyphenonium bromide is an antagonist of mAChR. Oxyphenonium bromide protects against the bronchial obstructive effects[1][2][3].
2(1H)-Pyrimidinone, 4-amino-1-[(2S)-2-hydroxy-3-(triphenylmethoxy)propyl]-
4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinecarboxylic acid 2-(2-hydroxyethoxy)ethyl ester
N,N-Bis[2-(7-methoxy-1-naphthalenyl)ethyl]acetamide
2-Azido-2-deoxy-3,4-bis-O-(phenylmethyl)-D-galactose 6-acetate
Benzoic acid, 4-[[(5-ethoxy-5-oxopentyl)[2-(2-Methoxyphenyl)ethyl]aMino]Methyl]-, Methyl ester
(11BETA,16BETA)-PREGNA-1,4-DIENE-3,20-DIONE,21-AMINO-9-FLUORO-11,17-DIHYDROXY-16-METHYL-,HYDROCHLORIDE
(5-{3-[5-(Piperidin-1-Ylmethyl)-1h-Indol-2-Yl]-1h-Indazol-6-Yl}-2h-1,2,3-Triazol-4-Yl)methanol
Ivaltinostat
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
3-(1,3-Benzodioxol-5-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-1-(4-methyl-1-piperidinyl)-1-propanone
7-(4-Benzylpiperazin-1-yl)-3-(2-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidine
(3r)-3-Cyclopentyl-6-Methyl-7-[(4-Methylpiperazin-1-Yl)sulfonyl]-3,4-Dihydro-2h-1,2-Benzothiazine 1,1-Dioxide
N-[4-[[4-(cyclopropylmethyl)piperazin-1-yl]methyl]phenyl]-4-propylbenzenesulfonamide
Tropantiol
[3-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]-8-azaniumyloctyl]azanium
methyl (1S,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-8-methyl-8-aza-16-azoniapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
3-(1,3-Benzodioxol-5-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-1-(3-methyl-1-piperidinyl)-1-propanone
Magnocurarine trifluoroacetate, rac-
A natural product found in Gnetum montanum.
N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxyl)phenyl]ethylamine hydrochloride
Phe-Phe-Asp
A tripeptide composed of two L-phenylalanine units and L-aspartic acid joined by peptide linkages.
1,4-Dimethyl-6-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]quinoxaline-2,3-dione
4-methyl-N-[3-[1-(phenylmethyl)-4-piperidinyl]-2,4-dihydro-1H-1,3,5-triazin-6-yl]benzenesulfonamide
1-[4-[2-(4-Methoxyphenyl)-5-phenyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]ethanone
(5E)-1-cyclohexyl-5-[1-[[2-(3-pyridyl)piperidino]amino]ethylidene]-2-thioxo-hexahydropyrimidine-4,6-quinone
1-Azelaoyl-sn-glycero-3-phosphocholine
A 1-O-acyl-sn-glycero-3-phosphocholine obtained by formal condensation of one of the carboxy groups of azelaic acid with the 1-hydroxy group of sn-glycero-3-phosphocholine.
2-Azelaoyl-sn-glycero-3-phosphocholine
A 2-acyl-sn-glycero-3-phosphocholine obtained by formal condensation of one of the carboxy groups of azelaic acid with the 1-hydroxy group of sn-glycero-3-phosphocholine.
1-(7-Methyloctyl)-3-[4-(4-morpholinylsulfonyl)phenyl]thiourea
N-[[4-(2-ethoxyphenyl)-1-piperazinyl]-sulfanylidenemethyl]-1-adamantanecarboxamide
1-[(2-chlorophenyl)methyl]-N-[3-(N-ethyl-3-methylanilino)propyl]-5-oxo-2-pyrrolidinecarboxamide
N-(2-furanylmethyl)-N-[(7-methyl-4-tetrazolo[1,5-a]quinolinyl)methyl]-2-phenoxyacetamide
N,N-dimethyl-4-[[4-(5-methyl-1-benzotriazolyl)-1-piperidinyl]sulfonyl]benzamide
4-[(4-Cyclohexyl-1-piperazinyl)-oxomethyl]-2-ethyl-6,7-dimethoxy-1-isoquinolinone
13-(3-Ethoxypropyl)-14-methyl-17-(4-methylphenyl)-2,9,13,15,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-1,3,5,7,9,11(16),14-heptaen-12-one
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
N-(1-cyclohexyl-3-hydroxy-3,4-diphenylbutyl)benzamide
3-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
3-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
N-[2-[1-[2-(2,5-difluorophenoxy)ethyl]-2-benzimidazolyl]ethyl]cyclohexanecarboxamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]pyrazine-2-carboxamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]pyrazine-2-carboxamide
N-[3-(dimethylamino)propyl]-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]oxan-2-yl]acetamide
N-[3-(dimethylamino)propyl]-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]acetamide
3-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
3-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]pyrazine-2-carboxamide
N-[3-(dimethylamino)propyl]-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]oxan-2-yl]acetamide
3-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
(2R,3R,4S)-2-cyano-N-(2-fluorophenyl)-4-(hydroxymethyl)-3-[4-[(E)-2-phenylethenyl]phenyl]azetidine-1-carboxamide
(2R,3R,3aS,9bS)-N-(cyclohexylmethyl)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[[(2S,3R)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methylmethanesulfonamide
N-[[(2R,3R)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methylmethanesulfonamide
N-[(4S,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4S,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[3-(dimethylamino)propyl]-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]acetamide
(2S,3S,3aR,9bR)-N-(cyclohexylmethyl)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
3-[(3aS,4R,9bS)-1-[(2-fluorophenyl)-oxomethyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
3-[(3aS,4S,9bS)-1-[(2-fluorophenyl)-oxomethyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
[(1S)-7-methoxy-1-(3-methylphenyl)sulfonyl-1-spiro[1,2,3,9-tetrahydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
1-[(1S)-2-acetyl-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-1-butanone
(6R,7S,8S)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8S)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
N-[[(2S,3R)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methylmethanesulfonamide
N-[[(2R,3S)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methylmethanesulfonamide
N-[[(2S,3S)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methylmethanesulfonamide
N-[(E)-[4-(2-hydroxyethoxy)phenyl]methylideneamino]-N-(2-hydroxyphenyl)octanediamide
N-[[(2S,3S)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methylmethanesulfonamide
N-[[(2R,3R)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methylmethanesulfonamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-pyrazinecarboxamide
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-pyrazinecarboxamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-pyrazinecarboxamide
N-[(4S,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4R,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4R,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4R,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4S,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[3-(dimethylamino)propyl]-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]acetamide
N-[3-(dimethylamino)propyl]-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]acetamide
N-[3-(dimethylamino)propyl]-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]acetamide
N-[3-(dimethylamino)propyl]-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]acetamide
3-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
3-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
3-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[(3-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[(3-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
(2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
3-[(3aR,4S,9bR)-1-[(2-fluorophenyl)-oxomethyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
3-[(3aR,4R,9bR)-1-[(2-fluorophenyl)-oxomethyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
N,N-dimethyl-3-[4-[(1S,5R)-3-[oxo(2-pyrazinyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzamide
1-[(1R)-2-acetyl-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-1-butanone
(6S,7S,8S)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8R)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
14-(Methoxycarbonyl)-4,4,8alpha,12,16-pentamethyl-3,17-dioxo-5beta,9beta,10alpha,13alpha-androsta-11,15-dien-15-olate
(1R,9S,10S,11S)-12-acetyl-N-(cyclohexylmethyl)-10-(hydroxymethyl)-6-oxo-5-[(Z)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-12-acetyl-N-(cyclohexylmethyl)-10-(hydroxymethyl)-6-oxo-5-[(Z)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
[(4R,7S,8R)-7-[(Z)-2-methylbut-2-enoyl]oxy-4-oxido-5,6,7,8-tetrahydro-3H-pyrrolizin-4-ium-1-yl]methyl (2R)-2,3-dihydroxy-2-[(1S)-1-methoxyethyl]-3-methylbutanoate
2-Amino-3-[hydroxy-(2-hydroxy-3-undecanoyloxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[(3-butanoyloxy-2-hexanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[2,3-di(pentanoyloxy)propoxy-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[(2-heptanoyloxy-3-propanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
3-[(3-Acetyloxy-2-octanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid
MORICIZINE
D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Mozavaptan
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
andrastin D(1-)
An enolate anion resulting from the deprotonation of the enol of andrastin D.Major species at pH 7.3. Published in http://dx.doi.org/10.1016/j.tet.2013.07.029